Treatment switching in oncology trials and the acceptability of adjustment methods.

about

Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.

P2860

Q37597690-7CD4D7D5-4B88-498A-B86C-285005E0C21C

P2860

Treatment switching in oncology trials and the acceptability of adjustment methods.

Item

http://www.wikidata.org/entity/Q48040468

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Treatment switching in oncology trials and the acceptability of adjustment methods.

@en

Treatment switching in oncology trials and the acceptability of adjustment methods.

@nl

type

Item

label

Treatment switching in oncology trials and the acceptability of adjustment methods.

@en

Treatment switching in oncology trials and the acceptability of adjustment methods.

@nl

prefLabel

Treatment switching in oncology trials and the acceptability of adjustment methods.

@en

Treatment switching in oncology trials and the acceptability of adjustment methods.

@nl

P1476

Treatment switching in oncology trials and the acceptability of adjustment methods.

@en

P2860

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.

Randomization-based methods for correcting for treatment changes: examples from the Concorde trial.

Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma.

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Methods for adjusting for bias due to crossover in oncology trials.

P304

561-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/14737167.2015.1037835

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas Latimer

P577

2015-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25893990

http://www.w3.org/2001/XMLSchema#string

Treatment switching in oncology trials and the acceptability of adjustment methods.

about

P2860

P2860

Treatment switching in oncology trials and the acceptability of adjustment methods.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698